Fellow Indian company Ranbaxy Laboratories for $3.2B in an all-stock deal that will create the world's fifth-largest generic-drug maker. The merger combines two firms that have had problems with quality issues. Ranbaxy, which is owned by Japan's Daiichi Sankyo (OTCPK:DSKYF), is banned from selling ingredients to the U.S., while Sun's Karkhadi facility is also not allowed to export products to the U.S.
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment